secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001213900-24-056728
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
--------------------------------------------------------------------------------

- First patient enrolled in randomized, double-blind, placebo-controlled trial at Tufts Medical Center.
- Study is first and only clinical trial evaluating tafenoquine in human babesiosis patients.
- Endpoints: time to sustained clinical resolution and molecular cure via FDA-approved nucleic acid test.
- Study targets at least 24 and up to 33 patients; interim analysis planned; recruitment during 2024 tick season.
- Tafenoquine (ARAKODA) already FDA-approved for malaria prophylaxis; orphan drug designation for babesiosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024056728/0001213900-24-056728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024056728/ea0208661-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-056728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer